Neupharma, which is developing inhaled teicoplanin for the treatment of MRSA lung infections in CF patients in partnership with Rare Partners, has announced that a Phase 1 PK study of the formulation in cystic fibrosis patients demonstrated that the concentration of teicoplanin measured in the sputum 24 hours post-dose was dose dependent and exceeded the minimum inhibitory concentration, with minimal levels detected in the plasma. The formulation was also well tolerated with no noted safety issues, the company said. The open-label study enrolled 12 CF patients and evaluated 2 dose levels of teicoplanin (150 mg and 300 mg) delivered via the PARI eFlow nebulizer system.
The company’s nebulized teicoplanin has been granted orphan drug designation for this indication in both the US and Europe. In 2019, Neupharma had announced a deal giving Italfarmaco an option to develop the inhaled teicoplanin for the treatment of MRSA infections in CF patients.
According to Neupharma, a Phase 2 trial in CF patients with MRSA lung infections is scheduled to begin sometime in the first half of 2022.
Read the Neupharma press release.
